{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:55:22Z","timestamp":1781585722095,"version":"3.54.5"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The comparative efficacy of pharmacological treatments for lower-risk myelodysplastic syndromes (LR-MDS) remains uncertain because head-to-head randomised evidence is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic review and network meta-analysis of randomised controlled trials evaluating pharmacological treatments for LR-MDS. Outcomes of interest were haematological improvement\u2013erythroid (HI\u2013E), red blood cell transfusion independence (RBC\u2013TI), haematological improvement\u2013platelet (HI\u2013P), and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 20 trials (2,877 participants), of which 17 trials (2,670 participants) contributed to connected treatment networks. For HI\u2013E, luspatercept and ESA-based regimens were associated with higher rates. Lenalidomide-containing regimens showed favourable RBC\u2013TI outcomes, including lenalidomide plus ESA, lenalidomide with or without ESA and\/or G-CSF, and lenalidomide monotherapy. For HI\u2013P, eltrombopag and romiplostim showed potential benefits. Safety profiles differed across treatments: CC-486 and imetelstat were associated with higher odds of neutropenia and gastrointestinal toxicity, whereas luspatercept was associated with increased fatigue and AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Comparative treatment benefit in LR-MDS differs by clinical endpoint. These findings support an individualised, goal-directed treatment approach rather than a single universally superior therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251184384.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1853205","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:29:20Z","timestamp":1781584160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Haixia","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sichuan University West China Hospital Guang\u2019an Hospital","place":["Guang\u2019an, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqiang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan University West China Hospital Guang\u2019an Hospital","place":["Guang\u2019an, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan University West China Hospital Guang\u2019an Hospital","place":["Guang\u2019an, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sichuan University West China Hospital Guang\u2019an Hospital","place":["Guang\u2019an, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bjh.20126","article-title":"How to use luspatercept and erythropoiesis-stimulating agents in low-risk myelodysplastic syndrome","volume":"207","author":"Santini","year":"2025","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01217-0","article-title":"Treatment of anemia in lower-risk myelodysplastic syndrome","volume":"25","author":"Battaglia","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.leukres.2019.03.006","article-title":"Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols","volume":"81","author":"Gasc\u00f3n","year":"2019","journal-title":"Leuk Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183590","article-title":"Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low\/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study","volume":"104","author":"Messa","year":"2019","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.04.014","article-title":"Transfusion independence corresponds with survival in patients with lower-risk myelodysplastic syndrome: Real-world evidence from United States insurance claims","volume":"25","author":"Komrokji","year":"2025","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202767","article-title":"High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies","volume":"13","author":"Wan","year":"2021","journal-title":"Aging Albany NY"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017611","article-title":"Luspatercept for patients with lower-risk myelodysplastic syndromes\/neoplasms: a systematic review and meta-analysis","volume":"9","author":"Alhajahjeh","year":"2025","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0215","article-title":"Azacitidine in lower-risk myelodysplastic syndromes: A meta-analysis of data from prospective studies","volume":"23","author":"Komrokji","year":"2018","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14116","article-title":"Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis","volume":"174","author":"Park","year":"2016","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27410","article-title":"Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial","volume":"99","author":"Mittelman","year":"2024","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"Bmj"},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PloS Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-0044-6","article-title":"Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study","volume":"85","author":"Balleari","year":"2006","journal-title":"Ann Hematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/leu.2015.296","article-title":"Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion","volume":"30","author":"Toma","year":"2016","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140988","article-title":"A randomized phase II trial of azacitidine +\/- epoetin-\u03b2 in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents","volume":"101","author":"Th\u00e9pot","year":"2016","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-\u03b1 in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13096","article-title":"Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low\/Int-1-risk MDS patients: Results of the phase II KALLISTO trial","volume":"101","author":"Gattermann","year":"2018","journal-title":"Eur J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02161-6","article-title":"Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial","volume":"38","author":"van de Loosdrecht","year":"2024","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00203-5","article-title":"Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial","volume":"11","author":"Della Porta","year":"2024","journal-title":"Lancet Haematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01691","article-title":"Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin","volume":"39","author":"List","year":"2021","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clml.2018.12.012","article-title":"Clinical benefit-risk profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): Results of a phase III trial","volume":"19","author":"Garcia-Manero","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02619","article-title":"Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"39","author":"Garcia-Manero","year":"2021","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7150\/jca.56207","article-title":"Lower-dose decitabine improves clinical response compared with best supportive care in lower-risk MDS patients: a prospective, multicenter phase 2 study","volume":"12","author":"Ye","year":"2021","journal-title":"J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double-blind study of romiplostim versus placebo in patients with low\/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.03.027","article-title":"Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes","volume":"33","author":"Schanz","year":"2009","journal-title":"Leuk Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1587","article-title":"Mannuronic acid in low-risk and intermediate-1-risk myelodysplastic syndromes","volume":"60","author":"Ghaderi","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520956894","article-title":"GPX3 methylation is associated with hematologic improvement in low-risk myelodysplastic syndrome patients treated with Pai-Neng-Da","volume":"48","author":"Yang","year":"2020","journal-title":"J Int Med Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011045","article-title":"Ineffective erythropoiesis and its treatment","volume":"139","author":"Cazzola","year":"2022","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27102","article-title":"Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia","volume":"99","author":"Garbowski","year":"2024","journal-title":"Am J Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.05.001","article-title":"Impact of lenalidomide treatment on overall survival in patients with lower-risk, transfusion-dependent myelodysplastic syndromes","volume":"22","author":"Santini","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.clml.2017.12.004","article-title":"The effect of lenalidomide on health-related quality of life in patients with lower-risk non-del(5q) myelodysplastic syndromes: Results from the MDS-005 study","volume":"18","author":"Santini","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.6004\/jnccn.2025.0013","article-title":"NCCN guidelines\u00ae Insights: myelodysplastic syndromes, version 2.2025","volume":"23","author":"Greenberg","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.01.024","article-title":"Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: A network meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:29:23Z","timestamp":1781584163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1853205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":47,"alternative-id":["10.3389\/fonc.2026.1853205"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1853205","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"article-number":"1853205"}}